PM<sub>2.5</sub> Associated With Gray Matter Atrophy Reflecting Increased Alzheimer Risk in Older Women.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 33208540.
- Also identified by DOI 10.1212/WNL.0000000000011149 and PMC identifier 8055348.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To examine whether late-life exposure to PM<sub>2.5</sub> (particulate matter with aerodynamic diameters <2.5 µm) contributes to progressive brain atrophy predictive of Alzheimer disease (AD) using a community-dwelling cohort of women (age 70-89 years) with up to 2 brain MRI scans (MRI-1, 2005-2006; MRI-2, 2010-2011). AD pattern similarity (AD-PS) scores, developed by supervised machine learning and validated with MRI data from the Alzheimer's Disease Neuroimaging Initiative, were used to capture high-dimensional gray matter atrophy in brain areas vulnerable to AD (e.g., amygdala, hippocampus, parahippocampal gyrus, thalamus, inferior temporal lobe areas, and midbrain). Using participants' addresses and air monitoring data, we implemented a spatiotemporal model to estimate 3-year average exposure to PM<sub>2.5</sub> preceding MRI-1. General linear models were used to examine the association between PM<sub>2.5</sub> and AD-PS scores (baseline and 5-year standardized change), accounting for potential confounders and white matter lesion volumes. For 1,365 women 77.9 ± 3.7 years of age in 2005 to 2006, there was no association between PM<sub>2.5</sub> and baseline AD-PS score in cross-sectional analyses (β = -0.004; 95% confidence interval [CI] -0.019 to 0.011). Longitudinally, each interquartile range increase of PM<sub>2.5</sub> (2.82 µg/m<sup>3</sup>) was associated with increased AD-PS scores during the follow-up, equivalent to a 24% (hazard ratio 1.24, 95% CI 1.14-1.34) increase in AD risk over 5 years (n = 712, age 77.4 ± 3.5 years). This association remained after adjustment for sociodemographics, intracranial volume, lifestyle, clinical characteristics, and white matter lesions and was present with levels below US regulatory standards (<12 µg/m<sup>3</sup>). Late-life exposure to PM<sub>2.5</sub> is associated with increased neuroanatomic risk of AD, which may not be explained by available indicators of cerebrovascular damage.